1
|
Gaobotse G, Venkataraman S, Mmereke KM, Moustafa K, Hefferon K, Makhzoum A. Recent Progress on Vaccines Produced in Transgenic Plants. Vaccines (Basel) 2022; 10:1861. [PMID: 36366370 PMCID: PMC9698746 DOI: 10.3390/vaccines10111861] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Revised: 10/27/2022] [Accepted: 10/31/2022] [Indexed: 01/15/2024] Open
Abstract
The development of vaccines from plants has been going on for over two decades now. Vaccine production in plants requires time and a lot of effort. Despite global efforts in plant-made vaccine development, there are still challenges that hinder the realization of the final objective of manufacturing approved and safe products. Despite delays in the commercialization of plant-made vaccines, there are some human vaccines that are in clinical trials. The novel coronavirus (SARS-CoV-2) and its resultant disease, coronavirus disease 2019 (COVID-19), have reminded the global scientific community of the importance of vaccines. Plant-made vaccines could not be more important in tackling such unexpected pandemics as COVID-19. In this review, we explore current progress in the development of vaccines manufactured in transgenic plants for different human diseases over the past 5 years. However, we first explore the different host species and plant expression systems during recombinant protein production, including their shortcomings and benefits. Lastly, we address the optimization of existing plant-dependent vaccine production protocols that are aimed at improving the recovery and purification of these recombinant proteins.
Collapse
Affiliation(s)
- Goabaone Gaobotse
- Department of Biological Sciences & Biotechnology, Botswana International University of Science & Technology, Palapye, Botswana
| | - Srividhya Venkataraman
- Virology Laboratory, Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada
| | - Kamogelo M. Mmereke
- Department of Biological Sciences & Biotechnology, Botswana International University of Science & Technology, Palapye, Botswana
| | - Khaled Moustafa
- The Arabic Preprint Server/Arabic Science Archive (ArabiXiv)
| | - Kathleen Hefferon
- Department of Microbiology, Cornell University, Ithaca, NY 14850, USA
| | - Abdullah Makhzoum
- Department of Biological Sciences & Biotechnology, Botswana International University of Science & Technology, Palapye, Botswana
| |
Collapse
|
2
|
Rosario-Acevedo R, Biryukov SS, Bozue JA, Cote CK. Plague Prevention and Therapy: Perspectives on Current and Future Strategies. Biomedicines 2021; 9:biomedicines9101421. [PMID: 34680537 PMCID: PMC8533540 DOI: 10.3390/biomedicines9101421] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Revised: 09/27/2021] [Accepted: 10/04/2021] [Indexed: 01/14/2023] Open
Abstract
Plague, caused by the bacterial pathogen Yersinia pestis, is a vector-borne disease that has caused millions of human deaths over several centuries. Presently, human plague infections continue throughout the world. Transmission from one host to another relies mainly on infected flea bites, which can cause enlarged lymph nodes called buboes, followed by septicemic dissemination of the pathogen. Additionally, droplet inhalation after close contact with infected mammals can result in primary pneumonic plague. Here, we review research advances in the areas of vaccines and therapeutics for plague in context of Y. pestis virulence factors and disease pathogenesis. Plague continues to be both a public health threat and a biodefense concern and we highlight research that is important for infection mitigation and disease treatment.
Collapse
|
3
|
Leite ML, Sampaio KB, Costa FF, Franco OL, Dias SC, Cunha NB. Molecular farming of antimicrobial peptides: available platforms and strategies for improving protein biosynthesis using modified virus vectors. AN ACAD BRAS CIENC 2018; 91:e20180124. [PMID: 30365717 DOI: 10.1590/0001-3765201820180124] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Accepted: 06/07/2018] [Indexed: 11/22/2022] Open
Abstract
The constant demand for new antibiotic drugs has driven efforts by the scientific community to prospect for peptides with a broad spectrum of action. In this context, antimicrobial peptides (AMPs) have acquired great scientific importance in recent years due to their ability to possess antimicrobial and immunomodulatory activity. In the last two decades, plants have attracted the interest of the scientific community and industry as regards their potential as biofactories of heterologous proteins. One of the most promising approaches is the use of viral vectors to maximize the transient expression of drugs in the leaves of the plant Nicotiana benthamiana. Recently, the MagnifectionTM expression system was launched. This sophisticated commercial platform allows the assembly of the viral particle in leaf cells and the systemic spread of heterologous protein biosynthesis in green tissues caused by Agrobacterium tumefaciens "gene delivery method". The system also presents increased gene expression levels mediated by potent viral expression machinery. These characteristics allow the mass recovery of heterologous proteins in the leaves of N. benthamiana in 8 to 10 days. This system was highly efficient for the synthesis of different classes of pharmacological proteins and contains enormous potential for the rapid and abundant biosynthesis of AMPs.
Collapse
Affiliation(s)
- Michel L Leite
- Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- Pós-Graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
| | - Kamila B Sampaio
- Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- Pós-Graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
| | - Fabrício F Costa
- Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- Cancer Biology and Epigenomics Program, Northwestern University's Feinberg School of Medicine, 60611, Chicago IL, USA
- Genomic Enterprise, 2405 N. Sheffield Av., 14088, 60614, Chicago, IL, USA
- MATTER Chicago, 222 W. Merchandise Mart Plaza, 12th Floor, 60654, Chicago, IL, USA
- The Founder Institute, 3337 El Camino Real, 94306, Palo Alto, CA USA
| | - Octávio L Franco
- Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- Pós-Graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- S-Inova Biotech, Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Av. Tamandaré, 6000, Jardim Seminário, 79117-010 Campo Grande, MS, Brazil
| | - Simoni C Dias
- Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- Pós-Graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
| | - Nicolau B Cunha
- Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- Pós-Graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
| |
Collapse
|
4
|
da Cunha NB, Cobacho NB, Viana JFC, Lima LA, Sampaio KBO, Dohms SSM, Ferreira ACR, de la Fuente-Núñez C, Costa FF, Franco OL, Dias SC. The next generation of antimicrobial peptides (AMPs) as molecular therapeutic tools for the treatment of diseases with social and economic impacts. Drug Discov Today 2017; 22:234-248. [PMID: 27890668 PMCID: PMC7185764 DOI: 10.1016/j.drudis.2016.10.017] [Citation(s) in RCA: 117] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Revised: 10/28/2016] [Accepted: 10/31/2016] [Indexed: 12/02/2022]
Abstract
Anti-infective drugs have had a key role in the contemporary world, contributing to dramatically decrease mortality rates caused by infectious diseases worldwide. Antimicrobial peptides (AMPs) are multifunctional effectors of the innate immune system of mucosal surfaces and present antimicrobial activity against a range of pathogenic viruses, bacteria, and fungi. However, the discovery and development of new antibacterial drugs is a crucial step to overcome the great challenge posed by the emergence of antibiotic resistance. In this review, we outline recent advances in the development of novel AMPs with improved antimicrobial activities that were achieved through characteristic structural design. In addition, we describe recent progress made to overcome some of the major limitations that have hindered peptide biosynthesis.
Collapse
Affiliation(s)
- Nicolau B da Cunha
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil; Genomic Sciences and Biotechnology Program - Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| | - Nicole B Cobacho
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| | - Juliane F C Viana
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil; Universidade Ceuma, Rua Josué Montello, 1, 65060-645 São Luís, MA, Brazil
| | - Loiane A Lima
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| | - Kamila B O Sampaio
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| | - Stephan S M Dohms
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| | - Arthur C R Ferreira
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| | - César de la Fuente-Núñez
- Synthetic Biology Group, MIT Synthetic Biology Center, Massachusetts Institute of Technology, 02139 Cambridge, MA, USA; Research Laboratory of Electronics, Massachusetts Institute of Technology, 02139 Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, 02139 Cambridge, MA, USA; Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, 02142 Cambridge, MA, USA; Broad Institute of MIT and Harvard, 02142 Cambridge, MA, USA; Harvard Biophysics Program, Harvard University, 02115 Boston, MA, USA
| | - Fabrício F Costa
- Genomic Sciences and Biotechnology Program - Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil.
| | - Octávio L Franco
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil; Genomic Sciences and Biotechnology Program - Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil; S-Inova Biotech, Post-Graduation in Biotechnology, Universidade Católica Dom Bosco, 79117-900 Campo Grande, MS, Brazil
| | - Simoni C Dias
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil; Genomic Sciences and Biotechnology Program - Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| |
Collapse
|
5
|
Joung YH, Park SH, Moon KB, Jeon JH, Cho HS, Kim HS. The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B. Int J Mol Sci 2016; 17:E1715. [PMID: 27754367 PMCID: PMC5085746 DOI: 10.3390/ijms17101715] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Revised: 09/23/2016] [Accepted: 09/29/2016] [Indexed: 12/22/2022] Open
Abstract
Disease prevention through vaccination is considered to be the greatest contribution to public health over the past century. Every year more than 100 million children are vaccinated with the standard World Health Organization (WHO)-recommended vaccines including hepatitis B (HepB). HepB is the most serious type of liver infection caused by the hepatitis B virus (HBV), however, it can be prevented by currently available recombinant vaccine, which has an excellent record of safety and effectiveness. To date, recombinant vaccines are produced in many systems of bacteria, yeast, insect, and mammalian and plant cells. Among these platforms, the use of plant cells has received considerable attention in terms of intrinsic safety, scalability, and appropriate modification of target proteins. Research groups worldwide have attempted to develop more efficacious plant-derived vaccines for over 30 diseases, most frequently HepB and influenza. More inspiring, approximately 12 plant-made antigens have already been tested in clinical trials, with successful outcomes. In this study, the latest information from the last 10 years on plant-derived antigens, especially hepatitis B surface antigen, approaches are reviewed and breakthroughs regarding the weak points are also discussed.
Collapse
Affiliation(s)
- Young Hee Joung
- School of Biological Sciences & Technology, Chonnam National University, Gwangju 61186, Korea.
| | - Se Hee Park
- School of Biological Sciences & Technology, Chonnam National University, Gwangju 61186, Korea.
| | - Ki-Beom Moon
- Molecular Biofarming Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon 34141, Korea.
| | - Jae-Heung Jeon
- Molecular Biofarming Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon 34141, Korea.
| | - Hye-Sun Cho
- Molecular Biofarming Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon 34141, Korea.
| | - Hyun-Soon Kim
- Molecular Biofarming Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon 34141, Korea.
| |
Collapse
|
6
|
Abstract
Three major plague pandemics caused by the gram-negative bacterium Yersinia pestis have killed nearly 200 million people in human history. Due to its extreme virulence and the ease of its transmission, Y. pestis has been used purposefully for biowarfare in the past. Currently, plague epidemics are still breaking out sporadically in most of parts of the world, including the United States. Approximately 2000 cases of plague are reported each year to the World Health Organization. However, the potential use of the bacteria in modern times as an agent of bioterrorism and the emergence of a Y. pestis strain resistant to eight antibiotics bring out severe public health concerns. Therefore, prophylactic vaccination against this disease holds the brightest prospect for its long-term prevention. Here, we summarize the progress of the current vaccine development for counteracting plague.
Collapse
Affiliation(s)
- Wei Sun
- Department of Infectious Diseases and Pathology, College of Veterinary Medicine, University of Florida, 110880, Gainesville, FL, 32611-0880, USA.
| |
Collapse
|
7
|
Streatfield SJ, Kushnir N, Yusibov V. Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents. PLANT BIOTECHNOLOGY JOURNAL 2015; 13:1136-59. [PMID: 26387510 PMCID: PMC7167919 DOI: 10.1111/pbi.12475] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Revised: 08/06/2015] [Accepted: 08/19/2015] [Indexed: 05/20/2023]
Abstract
Despite progress in the prevention and treatment of infectious diseases, they continue to present a major threat to public health. The frequency of emerging and reemerging infections and the risk of bioterrorism warrant significant efforts towards the development of prophylactic and therapeutic countermeasures. Vaccines are the mainstay of infectious disease prophylaxis. Traditional vaccines, however, are failing to satisfy the global demand because of limited scalability of production systems, long production timelines and product safety concerns. Subunit vaccines are a highly promising alternative to traditional vaccines. Subunit vaccines, as well as monoclonal antibodies and other therapeutic proteins, can be produced in heterologous expression systems based on bacteria, yeast, insect cells or mammalian cells, in shorter times and at higher quantities, and are efficacious and safe. However, current recombinant systems have certain limitations associated with production capacity and cost. Plants are emerging as a promising platform for recombinant protein production due to time and cost efficiency, scalability, lack of harboured mammalian pathogens and possession of the machinery for eukaryotic post-translational protein modification. So far, a variety of subunit vaccines, monoclonal antibodies and therapeutic proteins (antivirals) have been produced in plants as candidate countermeasures against emerging, reemerging and bioterrorism-related infections. Many of these have been extensively evaluated in animal models and some have shown safety and immunogenicity in clinical trials. Here, we overview ongoing efforts to producing such plant-based countermeasures.
Collapse
Affiliation(s)
| | - Natasha Kushnir
- Fraunhofer USA Center for Molecular Biotechnology, Newark, DE, USA
| | - Vidadi Yusibov
- Fraunhofer USA Center for Molecular Biotechnology, Newark, DE, USA
| |
Collapse
|
8
|
Matoba N, Shah NR, Mor TS. Humoral immunogenicity of an HIV-1 envelope residue 649-684 membrane-proximal region peptide fused to the plague antigen F1-V. Vaccine 2011; 29:5584-90. [PMID: 21693158 DOI: 10.1016/j.vaccine.2011.06.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2010] [Revised: 05/09/2011] [Accepted: 06/07/2011] [Indexed: 12/13/2022]
Abstract
The membrane-proximal region spanning residues 649-684 of the HIV-1 envelope protein gp41 (MPR₆₄₉₋₆₈₄) is an attractive vaccine target for humoral immunity that blocks viral transcytosis across the mucosal epithelia. However, induction of high-titer MPR₆₄₉₋₆₈₄-specific antibodies remains a challenging task. To explore potential solutions for this challenge, we tested a new translational fusion protein comprising the plague F1-V antigen and MPR₆₄₉₋₆₈₄ (F1-V-MPR₆₄₉₋₆₈₄). We employed systemic immunization for initial feasibility analyses. Despite strong immunogenicity demonstrated for the immunogen, repeated systemic immunizations of mice with F1-V-MPR₆₄₉₋₆₈₄ hardly induced MPR₆₄₉₋₆₈₄-specific IgG. In contrast, a single immunization with F1-V-MPR₆₄₉₋₆₈₄ mounted a significant anti-MPR₆₄₉₋₆₈₄ IgG response in animals that were primed with another MPR₆₄₉₋₆₈₄ fusion protein based on the cholera toxin B subunit. Additional boost immunizations with F1-V-MPR₆₄₉₋₆₈₄ recalled and maintained the antibody response and expanded the number of specific antibody-secreting B cells. Thus, while F1-V-MPR₆₄₉₋₆₈₄ alone was not sufficiently immunogenic to induce detectable levels of MPR₆₄₉₋₆₈₄-specific antibodies, these results suggest that prime-boost immunization using heterologous antigen-display platforms may overcome the poor humoral immunogenicity of MPR₆₄₉₋₆₈₄ for the induction of durable humoral immunity. Further studies are warranted to evaluate the feasibility of this strategy in mucosal immunization. Lastly, our findings add to a growing body of evidence in support of this strategy for immunogen design for poorly immunogenic epitopes besides the MPR of HIV-1's transmembrane envelope protein.
Collapse
Affiliation(s)
- Nobuyuki Matoba
- Center for Infectious Diseases and Vaccinology at the Biodesign Institute and School of Life Sciences, P.O. Box 874501, Arizona State University, Tempe, AZ 85287-4501, USA.
| | | | | |
Collapse
|
9
|
Rosenzweig JA, Jejelowo O, Sha J, Erova TE, Brackman SM, Kirtley ML, van Lier CJ, Chopra AK. Progress on plague vaccine development. Appl Microbiol Biotechnol 2011; 91:265-86. [PMID: 21670978 DOI: 10.1007/s00253-011-3380-6] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2011] [Revised: 05/11/2011] [Accepted: 05/11/2011] [Indexed: 12/15/2022]
Abstract
Yersinia pestis (YP), the gram-negative plague bacterium, has shaped human history unlike any other pathogen known to mankind. YP (transmitted by the bite of an infected flea) diverged only recently from the related enteric pathogen Yersinia pseudotuberculosis but causes radically different diseases. Three forms of plague exist in humans: bubonic (swollen lymph nodes or bubos), septicemic (spread of YP through the lymphatics or bloodstream from the bubos to other organs), and contagious, pneumonic plague which can be communicated via YP-charged respiratory droplets resulting in person-person transmission and rapid death if left untreated (50-90% mortality). Despite the potential threat of weaponized YP being employed in bioterrorism and YP infections remaining prevalent in endemic regions of the world where rodent populations are high (including the four corner regions of the USA), an efficacious vaccine that confers immunoprotection has yet to be developed. This review article will describe the current vaccine candidates being evaluated in various model systems and provide an overall summary on the progress of this important endeavor.
Collapse
Affiliation(s)
- Jason A Rosenzweig
- Department of Biology, Center for Bionanotechnology and Environmental Research (CBER), Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Castellani M, Anogeianaki A, Felaco P, Toniato E, De Lutiis M, Shaik B, Fulcheri M, Vecchiet J, Tetè S, Salini V, Theoharides T, Caraffa A, Antinolfi P, Frydas S, Conti P, Cuccurullo C, Ciampoli C, Cerulli G. IL-34 a Newly Discovered Cytokine. EUR J INFLAMM 2010. [DOI: 10.1177/1721727x1000800202] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
In this study we describe some biological effects of IL-34, a newly discovered cytokine. We show that Il-34 stimulates monocyte cell viability and directly modulates the number and function of monocytes and regulates myeloid cell growth and differentiation. Moreover, since IL-34 in mice is involved in osteoporosis, an antagonist of this cytokine could be beneficial for the treatment of this disease.
Collapse
Affiliation(s)
| | - A. Anogeianaki
- Department of Physiology, Faculty of Medicine, Aristotle University of Thessaloniki, Greece
| | - P. Felaco
- Department of Human Dynamics, University of Chieti, Italy
| | | | - M.A. De Lutiis
- Department of Human Dynamics, University of Chieti, Italy
| | - B. Shaik
- Department of Medicine, Boston University School of Medicine, Boston, MA, USA
| | - M. Fulcheri
- Department of Clinical Psychology, University of Chieti, Italy
| | - J. Vecchiet
- Infectious Diseases Division University of Chieti, Italy
| | - S. Tetè
- School of Dentistry, University of Chieti, Italy
| | - V. Salini
- Orthopaedics Division, University of Chieti
| | | | - A. Caraffa
- Orthopaedics Division, University of Perugia, Perugia, Italy
| | - P. Antinolfi
- Orthopaedics Division, University of Perugia, Perugia, Italy
| | - S. Frydas
- Parasitology and Parasit Diseases, Faculty of Veterinary Medicine, Aristotle University of Thessaloniki, Greece
| | | | - C. Cuccurullo
- Division of Medical Pathology, University of Chieti, Italy
| | - C. Ciampoli
- School of Dentistry, University of Chieti, Italy
| | - G. Cerulli
- Orthopaedics Division, University of Perugia, Perugia, Italy
| |
Collapse
|
11
|
Tremblay R, Wang D, Jevnikar AM, Ma S. Tobacco, a highly efficient green bioreactor for production of therapeutic proteins. Biotechnol Adv 2010; 28:214-21. [PMID: 19961918 PMCID: PMC7132750 DOI: 10.1016/j.biotechadv.2009.11.008] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2009] [Revised: 11/06/2009] [Accepted: 11/19/2009] [Indexed: 01/06/2023]
Abstract
Molecular farming of pharmaceuticals in plants has the potential to provide almost unlimited amounts of recombinant proteins for use in disease diagnosis, prevention or treatment. Tobacco has been and will continue to be a major crop for molecular farming and offers several practical advantages over other crops. It produces significant leaf biomass, has high soluble protein content and is a non-food crop, minimizing the risk of food-chain contamination. This, combined with its flexibility and highly-efficient genetic transformation/regeneration, has made tobacco particularly well suited for plant-based production of biopharmaceutical products. The goal of this review is to provide an update on the use of tobacco for molecular farming of biopharmaceuticals as well the technologies developed to enhance protein production/purification/efficacy. We show that tobacco is a robust biological reactor with a multitude of applications and may hold the key to success in plant molecular farming.
Collapse
Affiliation(s)
- Reynald Tremblay
- Department of Biology, University of Western Ontario, London, Ontario, Canada N6A 5B7
| | - David Wang
- Department of Molecular Biology, Princeton University, Princeton, NJ 08544-1014, USA
| | - Anthony M. Jevnikar
- Transplantation Immunology Group, Lawson Health Research Institute, London, Ontario, Canada N6A 4G5
| | - Shengwu Ma
- Department of Biology, University of Western Ontario, London, Ontario, Canada N6A 5B7
- Transplantation Immunology Group, Lawson Health Research Institute, London, Ontario, Canada N6A 4G5
- Plantigen Inc., 700 Collip Circle, London, Ontario, Canada N6G 4X8
| |
Collapse
|
12
|
Abstract
The potential application of Yersinia pestis for bioterrorism emphasizes the urgent need to develop more effective vaccines against airborne infection. The current status of plague vaccines has been reviewed. The present emphasis is on subunit vaccines based on the F1 and LcrV antigens. These provide good protection in animal models but may not protect against F1 strains with modifications to the type III secretion system. The duration of protection against pneumonic infection is also uncertain. Other strategies under investigation include defined live-attenuated vaccines, DNA vaccines, mucosal delivery systems and heterologous immunization. The live-attenuated strain Y. pestis EV NIIEG protects against aerosol challenge in animal models and, with further modification to reduce residual virulence and to optimize respiratory protection, it could provide a shortcut to improved vaccines. The regulatory problems inherent in licensing vaccines for which efficacy data are unavailable and their possible solutions are discussed herein.
Collapse
Affiliation(s)
- Valentina A Feodorova
- Scientific and Research Institute for Medical and Veterinary Biotechnologies, Russia-Switzerland, Branch in Saratov, 9 Proviantskaya Street, Box 1580, Saratov 410028, Russia.
| | | |
Collapse
|
13
|
Davoodi-Semiromi A, Schreiber M, Nallapali S, Verma D, Singh ND, Banks RK, Chakrabarti D, Daniell H. Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. PLANT BIOTECHNOLOGY JOURNAL 2010; 8:223-42. [PMID: 20051036 PMCID: PMC2807910 DOI: 10.1111/j.1467-7652.2009.00479.x] [Citation(s) in RCA: 112] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
Cholera and malaria are major diseases causing high mortality. The only licensed cholera vaccine is expensive; immunity is lost in children within 3 years and adults are not fully protected. No vaccine is yet available for malaria. Therefore, in this study, the cholera toxin-B subunit (CTB) of Vibrio cholerae fused to malarial vaccine antigens apical membrane antigen-1 (AMA1) and merozoite surface protein-1 (MSP1) was expressed in lettuce and tobacco chloroplasts. Southern blot analysis confirmed homoplasmy and stable integration of transgenes. CTB-AMA1 and CTB-MSP1 fusion proteins accumulated up to 13.17% and 10.11% (total soluble protein, TSP) in tobacco and up to 7.3% and 6.1% (TSP) in lettuce, respectively. Nine groups of mice (n = 10/group) were immunized subcutaneously (SQV) or orally (ORV) with purified antigens or transplastomic tobacco leaves. Significant levels of antigen-specific antibody titres of immunized mice completely inhibited proliferation of the malarial parasite and cross-reacted with the native parasite proteins in immunoblots and immunofluorescence studies. Protection against cholera toxin challenge in both ORV (100%) and SQV (89%) mice correlated with CTB-specific titres of intestinal, serum IgA and IgG1 in ORV and only IgG1 in SQV mice, but no other immunoglobulin. Increasing numbers of interleukin-10(+) T cell but not Foxp3(+) regulatory T cells, suppression of interferon-gamma and absence of interleukin-17 were observed in protected mice, suggesting that immunity is conferred via the Tr1/Th2 immune response. Dual immunity against two major infectious diseases provided by chloroplast-derived vaccine antigens for long-term (>300 days, 50% of mouse life span) offers a realistic platform for low cost vaccines and insight into mucosal and systemic immunity.
Collapse
MESH Headings
- Administration, Oral
- Animals
- Antibodies, Bacterial/blood
- Antibodies, Protozoan/blood
- Antigens, Protozoan/genetics
- Antigens, Protozoan/immunology
- CD4-Positive T-Lymphocytes/immunology
- Chloroplasts/immunology
- Chloroplasts/metabolism
- Cholera/immunology
- Cholera/prevention & control
- Cholera Toxin/genetics
- Cholera Toxin/immunology
- Cholera Vaccines/biosynthesis
- Cholera Vaccines/genetics
- Cholera Vaccines/immunology
- Cross Reactions
- Female
- Immunity, Humoral
- Immunoglobulin A/blood
- Immunoglobulin G/blood
- Injections, Subcutaneous
- Lactuca/genetics
- Lactuca/immunology
- Malaria/immunology
- Malaria/prevention & control
- Malaria Vaccines/biosynthesis
- Malaria Vaccines/genetics
- Malaria Vaccines/immunology
- Merozoite Surface Protein 1/genetics
- Merozoite Surface Protein 1/immunology
- Mice
- Mice, Inbred BALB C
- Plants, Genetically Modified/genetics
- Plants, Genetically Modified/immunology
- Recombinant Fusion Proteins/immunology
- Nicotiana/genetics
- Nicotiana/immunology
Collapse
Affiliation(s)
- Abdoreza Davoodi-Semiromi
- Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Orlando, FL, USA
| | - Melissa Schreiber
- Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Orlando, FL, USA
| | - Samson Nallapali
- Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Orlando, FL, USA
| | - Dheeraj Verma
- Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Orlando, FL, USA
| | - Nameirakpam D. Singh
- Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Orlando, FL, USA
| | - Robert K. Banks
- Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Orlando, FL, USA
| | - Debopam Chakrabarti
- Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Orlando, FL, USA
| | - Henry Daniell
- Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Orlando, FL, USA
| |
Collapse
|
14
|
Alvarez ML, Cardineau GA. Prevention of bubonic and pneumonic plague using plant-derived vaccines. Biotechnol Adv 2010; 28:184-96. [PMID: 19931370 DOI: 10.1016/j.biotechadv.2009.11.006] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2009] [Revised: 11/09/2009] [Accepted: 11/10/2009] [Indexed: 01/14/2023]
Abstract
Yersinia pestis, the causative agent of bubonic and pneumonic plague, is an extremely virulent bacterium but there are currently no approved vaccines for protection against this organism. Plants represent an economical and safer alternative to fermentation-based expression systems for the production of therapeutic proteins. The recombinant plague vaccine candidates produced in plants are based on the two most immunogenic antigens of Y. pestis: the fraction-1 capsular antigen (F1) and the low calcium response virulent antigen (V) either in combination or as a fusion protein (F1-V). These antigens have been expressed in plants using all three known possible strategies: nuclear transformation, chloroplast transformation and plant-virus-based expression vectors. These plant-derived plague vaccine candidates were successfully tested in animal models using parenteral, oral, or prime/boost immunization regimens. This review focuses on the recent research accomplishments towards the development of safe and effective pneumonic and bubonic plague vaccines using plants as bioreactors.
Collapse
Affiliation(s)
- M Lucrecia Alvarez
- Center for Infectious Diseases and Vaccinology, The Biodesign Institute at Arizona State University, 1001 South McAllister Avenue, Tempe, AZ 85287-5401, USA.
| | | |
Collapse
|
15
|
Zav'yalov V, Zavialov A, Zav'yalova G, Korpela T. Adhesive organelles of Gram-negative pathogens assembled with the classical chaperone/usher machinery: structure and function from a clinical standpoint. FEMS Microbiol Rev 2009; 34:317-78. [PMID: 20070375 DOI: 10.1111/j.1574-6976.2009.00201.x] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
This review summarizes current knowledge on the structure, function, assembly and biomedical applications of the superfamily of adhesive fimbrial organelles exposed on the surface of Gram-negative pathogens with the classical chaperone/usher machinery. High-resolution three-dimensional (3D) structure studies of the minifibers assembling with the FGL (having a long F1-G1 loop) and FGS (having a short F1-G1 loop) chaperones show that they exploit the same principle of donor-strand complementation for polymerization of subunits. The 3D structure of adhesive subunits bound to host-cell receptors and the final architecture of adhesive fimbrial organelles reveal two functional families of the organelles, respectively, possessing polyadhesive and monoadhesive binding. The FGL and FGS chaperone-assembled polyadhesins are encoded exclusively by the gene clusters of the γ3- and κ-monophyletic groups, respectively, while gene clusters belonging to the γ1-, γ2-, γ4-, and π-fimbrial clades exclusively encode FGS chaperone-assembled monoadhesins. Novel approaches are suggested for a rational design of antimicrobials inhibiting the organelle assembly or inhibiting their binding to host-cell receptors. Vaccines are currently under development based on the recombinant subunits of adhesins.
Collapse
|